These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 37722358

  • 1. Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.
    Ahn M, Lee T, Kim KS, Lee S, Na K.
    Adv Healthc Mater; 2023 Dec; 12(31):e2302374. PubMed ID: 37722358
    [Abstract] [Full Text] [Related]

  • 2. Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment.
    Kim D, Lee S, Na K.
    Small; 2021 Mar; 17(10):e2006650. PubMed ID: 33590726
    [Abstract] [Full Text] [Related]

  • 3. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.
    Kataoka M, Kitazawa M, Nakamura S, Koyama M, Yamamoto Y, Miyazaki S, Hondo N, Tanaka H, Soejima Y.
    Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
    [Abstract] [Full Text] [Related]

  • 4. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK, Cho YH, Cha PH, Yoon JS, Ro EJ, Jeong WJ, Park J, Kim H, Il Kim T, Min DS, Han G, Choi KY.
    Exp Mol Med; 2018 Nov 20; 50(11):1-12. PubMed ID: 30459318
    [Abstract] [Full Text] [Related]

  • 5. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW, Son E, Lee K, Lee Y, Kim Y, Lee JC, Lim Y, Hur M, Kim D, Nam DH.
    Int J Mol Sci; 2019 Nov 24; 20(23):. PubMed ID: 31771279
    [Abstract] [Full Text] [Related]

  • 6. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF, Feng ZQ, Chu TH, Yi B, Liu J, Yu H, Xue J, Wang YJ, Zhang CZ.
    Phytomedicine; 2024 Apr 24; 126():155462. PubMed ID: 38394734
    [Abstract] [Full Text] [Related]

  • 7. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 24; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 8. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 10. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
    Hondo N, Kitazawa M, Koyama M, Nakamura S, Tokumaru S, Miyazaki S, Kataoka M, Seharada K, Soejima Y.
    Cancer Lett; 2023 Jul 28; 567():216264. PubMed ID: 37336286
    [Abstract] [Full Text] [Related]

  • 11. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, Sconocchia G.
    Int J Cancer; 2020 May 01; 146(9):2531-2538. PubMed ID: 31396956
    [Abstract] [Full Text] [Related]

  • 12. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation.
    Ohishi T, Kato Y, Kaneko MK, Ohba SI, Inoue H, Harakawa A, Kawada M.
    Int J Mol Sci; 2020 Aug 21; 21(17):. PubMed ID: 32839411
    [Abstract] [Full Text] [Related]

  • 13. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
    Achmad A, Hanaoka H, Yoshioka H, Yamamoto S, Tominaga H, Araki T, Ohshima Y, Oriuchi N, Endo K.
    Cancer Sci; 2012 Mar 21; 103(3):600-5. PubMed ID: 22126621
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.
    Bellier J, Nokin MJ, Caprasse M, Tiamiou A, Blomme A, Scheijen JL, Koopmansch B, MacKay GM, Chiavarina B, Costanza B, Rademaker G, Durieux F, Agirman F, Maloujahmoum N, Cusumano PG, Lovinfosse P, Leung HY, Lambert F, Bours V, Schalkwijk CG, Hustinx R, Peulen O, Castronovo V, Bellahcène A.
    Cell Rep; 2020 Feb 04; 30(5):1400-1416.e6. PubMed ID: 32023458
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.
    Shi M, Shi H, Ji J, Cai Q, Chen X, Yu Y, Liu B, Zhu Z, Zhang J.
    Curr Cancer Drug Targets; 2014 Feb 04; 14(2):217-24. PubMed ID: 24467518
    [Abstract] [Full Text] [Related]

  • 20. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.